Stem Cell Transplant in Patients With Severe Sickle Cell Disease
NCT03421756
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class
Stopped
Trial terminated due to low rate of enrollment
Conditions
Sickle Cell Disease
Interventions
DRUG:
Alemtuzumab
RADIATION:
Total Body Irradiation
DRUG:
Sirolimus
Sponsor
Kathleen Dorritie